Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Diflunisal

Diflunisal: 1 brand, 9 generics; first approved Apr 19, 1982; generic available.

Generic availableHas discontinued products
Generic status & protection

Generic available: 9 ANDA applications approved.

Brands (NDA)
1
Generics (ANDA)
9
Listed patents
0
Presentations
15

Brand (NDA) products

Originator applications
  • NDA 01844519822 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    250MGTABLETORALDiscontinued
    500MGTABLETORALDiscontinued

Generic (ANDA) products (9)

Abbreviated applications
  • DIFLUNISAL
    ANDA 20284520243 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    500MGTABLETORALRxAB
    250MGTABLETORALRx
    375MGTABLETORALRx
  • DIFLUNISAL
    ANDA 2035472017
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    500MGTABLETORALRxAB
  • DIFLUNISAL
    ANDA 07440019972 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    250MGTABLETORALDiscontinued
    500MGTABLETORALDiscontinued
  • DIFLUNISAL
    ANDA 0746041996
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    500MGTABLETORALDiscontinued
  • DIFLUNISAL
    ANDA 07428519962 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    250MGTABLETORALDiscontinued
    500MGTABLETORALDiscontinued
  • DIFLUNISAL
    ANDA 0735621992
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    250MGTABLETORALDiscontinued
  • DIFLUNISAL
    ANDA 0735631992
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    500MGTABLETORALDiscontinued
  • DIFLUNISAL
    ANDA 0736791992
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    250MGTABLETORALDiscontinued
  • DIFLUNISALRS
    ANDA 0736731992
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    500MGTABLETORALRxAB

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Approval history

FDA approval span
First approval
45 yr ago
Most recent approval
2 yr 1 mo ago

Approvals span 1982–2024 across 10 FDA applications.

Brand (NDA) 110%
Generic (ANDA) 990%

Diflunisal: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.